Post-traumatic stress disorder (PTSD) is a chronic psychiatric condition that noticeably impairs quality of life, although only a limited proportion of newly diagnosed patients seek prescription…
According to Clarivate epidemiology, cognitive dysfunction (e.g., impaired attention / vigilance, memory, executive function) occurs in the vast majority of diagnosed schizophrenia patients and has…
Huntington’s disease (HD) is a rare progressive neurological disorder characterized by movement disorders, cognitive decline, behavioral changes, and psychiatric disturbances. Current treatment…
DRG Epidemiology's coverage of Schizophrenia comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of…
The schizophrenia market is highly crowded given the presence of numerous antipsychotic therapies including the continued genericization of key oral therapies, the availability of newer oral…
Over the past two decades, in response to mounting failures, clinical trials of disease-modifying therapies (DMTs) in Alzheimer’s disease (AD) have progressively moved earlier in the disease…
Parkinson’s disease (PD) is predominantly recognized as a motor disorder, but PD is also associated with a diverse mix of disabling nonmotor symptoms, including cognitive impairment and dementia…
Bipolar disorder (BPD) is a spectrum disorder that encompasses two symptom domains: mania and depression. BPD treatment is usually initiated with atypical antipsychotics and antiepileptic drugs (…
The schizophrenia market is highly crowded given the presence of numerous antipsychotic therapies including the continued genericization of key oral therapies, the availability of newer oral…
Huntington’s disease (HD) is an autosomal dominant, neurodegenerative disease characterized by progressive chorea, dystonia, and cognitive decline. Current treatment is entirely focused on…
Alzheimer’s disease (AD) is a chronic neurodegenerative condition widely recognized as a global health crisis; as the general population ages and AD prevalence grows, the need for drugs to treat…
The schizophrenia therapy market is mature and very crowded given the presence of numerous atypical and typical antipsychotic agents, including the continued genericization of key oral therapies,…
Huntington’s disease (HD) is a neurodegenerative genetic disorder caused by an abnormal trinucleotide repeat in the Htt gene. Aggregation of the product of the mutant allele, mHtt, drives the…
Decision Resources Group (DRG) estimates that 80% of the more than 3 million diagnosed prevalent cases of schizophrenia within our surveyed markets (i.e., United States, France, Germany, and United…
Introduction Alzheimer’s disease is a chronic disease than affects several million Brazilian and Mexican patients. Physicians have a small number of molecules available for the treatment of…